BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide

By: via Benzinga
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares rose 4.7 percent after the company reported the findings from the Phase 2 trial ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.